Literature DB >> 198370

Immunoglobulin class-specific antibody response in serum, spleen, lungs, and bronchoalveolar washings after primary and secondary sendai virus infection of germfree mice.

D Charlton, G Blandford.   

Abstract

Immunoglobulin class-specific antibodies were measured by a solid-phase radioimmunoassay in serum, bronchoalveolar washings (BAW), lung cell lysates, and spleen cell lysates in germfree mice after intranasal (i.n.) and intraperitoneal (i.p.) primary and secondary 10(5), 10(4), and 10(3) mean tissue culture infective doses (TCID(50)) of live parainfluenza 1 (Sendai) virus. The earliest antibody detected in lungs after i.n. virus challenge was immunoglobulin G (IgG), followed by IgM and, lastly, IgA. The local IgA response after both primary and secondary i.n. virus challenge was lowest after the severest infection. It is suggested that the delayed appearance of IgA antibody and the lower response after severe lung damage may be related to a temporary local secretory component-producing cell deficiency. The lungs were a major source of serum IgG antibody after both primary and secondary i.n. virus challenge. Only IgG and IgM antibodies were detectable in lung cell lysates after the i.n. 10(3) TCID(50) secondary response. A secondary response was detected in IgG, IgA, and IgM after secondary i.n. challenge with the other two doses. The lung response to all of primary and secondary i.p. doses of virus was exclusively IgG and IgM. Calculation of radioimmunoassay antibody per microgram of IgG, IgA, and IgM in serum and BAW after both i.n. and i.p. virus challenges showed that, when BAW antibody was present, the ratio in BAW was always higher than that in serum. This finding in the i.n. mice, together with the presence of IgA antibody-containing cells in the lungs, strongly indicates local manufacture and secretion of IgA antibodies in these animals and suggests that the same conclusion could apply to local IgG and IgM antibodies after both i.n. and i.p. challenges.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198370      PMCID: PMC421155          DOI: 10.1128/iai.17.3.521-527.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Studies on the immune response and pathogenesis of Sendai virus infection of mice. III. The effects of cyclophosphamide.

Authors:  G Blandford
Journal:  Immunology       Date:  1975-05       Impact factor: 7.397

2.  Responses of mice immunized with influenza virus by serosol and parenteral routes.

Authors:  G H Scott; R J Sydiskis
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Studies in experimental immunology of influenza. VII. An improved complement-fixation technique.

Authors:  M DONNELLEY
Journal:  Aust J Exp Biol Med Sci       Date:  1951-03

Review 5.  Immunity to infections on secretory surfaces.

Authors:  R H Waldman; R Ganguly
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

6.  Studies on the immune response and pathogenesis of Sendai virus infection of mice. II. The immunoglobulin class of plasma cells in the bronchial sub-mucosa.

Authors:  G Blandford; R B Heath
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

7.  Studies on the immune response and pathogenesis of Sendai virus infection of mice. I. The fate of viral antigens.

Authors:  G Blandford; R B Heath
Journal:  Immunology       Date:  1972-04       Impact factor: 7.397

8.  Arthus reaction and pneumonia.

Authors:  G Blandford
Journal:  Br Med J       Date:  1970-03-21

9.  The pathogenesis of Sendai virus infection in the mouse lung.

Authors:  T W Robinson; R J Cureton; R B Heath
Journal:  J Med Microbiol       Date:  1968-08       Impact factor: 2.472

10.  Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines.

Authors:  J A Bellanti; R L Sanga; B Klutinis; B Brandt; M S Artenstein
Journal:  N Engl J Med       Date:  1969-03-20       Impact factor: 91.245

View more
  8 in total

1.  Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.

Authors:  G A Cole; J M Katz; T L Hogg; K W Ryan; A Portner; D L Woodland
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

2.  Comparison of protective effects of serum antibody on respiratory and systemic infection of Sendai virus in mice.

Authors:  M Tashiro; K Tobita; J T Seto; R Rott
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  Sendai virus infection in genetically resistant and susceptible mice.

Authors:  D G Brownstein; A L Smith; E A Johnson
Journal:  Am J Pathol       Date:  1981-11       Impact factor: 4.307

4.  Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2.

Authors:  M Tashiro; M Homma
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

5.  Anti-TNP-forming cells in bronchus-associated lymphoid tissue (BALT) and paratracheal lymph node (PTLN) of the rat after intratracheal priming and boosting with TNP-KLH.

Authors:  G J van der Brugge-Gamelkoorn; E Claassen; T Sminia
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

6.  Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.

Authors:  M Tashiro; Y Fujii; K Nakamura; M Homma
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  Solid-phase micro-radioimmunoassay to measure immunoglobulin class-specific antibody to Mycoplasma pulmonis.

Authors:  G Taylor
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

8.  4-Ipomeanol-induced effects on Sendai viral pneumonia in mice.

Authors:  S K Durham; J G Babish; W L Castleman
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.